Reuters logo
BRIEF-Novo Nordisk says Tresiba and Victoza receive positive opinions from CHMP
March 21, 2014 / 12:50 PM / 4 years ago

BRIEF-Novo Nordisk says Tresiba and Victoza receive positive opinions from CHMP

COPENHAGEN, March 21 (Reuters) - Danish pharmaceutical company Novo Nordisk A/S said on Friday: * Diabetes products Tresiba and Victoza receive positive opinions from The Committee for Medicinal Products for Human Use (CHMP) for label updates expanding indications for use in adults with type 2 diabetes * Once the European Commission approves the label expansion, physicians will be able to prescribe Tresiba, the once-daily, long-acting basal insulin in combination with GLP-1 receptor agonists, such as Victoza. * Similarly, Victoza, the once-daily human glucagon-like peptide-1 (GLP-1 analogue), can be prescribed in combination with a basal insulin. Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below